Can UroLift be safely performed in men with prostate cancer before radiotherapy?
Background To evaluate the feasibility, safety, and early outcomes of UroLift as a strategy to optimise bladder outlet obstruction prior to prostate radiotherapy in men with prostate cancer. Methods We conducted a multicentre pilot feasibility study of consecutive men undergoing UroLift before planned prostate radiotherapy across three UK centres. The cohort comprised prospectively enrolled participants from the COSTAR feasibility trial (NCT05840549) and a contemporaneous off-trial pilot cohort managed according to the same eligibility criteria and clinical pathway; data were collected prospectively in both cohorts. Outcomes included perioperative safety, catheterisation, patient-reported improvement (PGI-I), and radiotherapy completion. Results Twenty-one men underwent UroLift pre radiotherapy (median age 74.8 years; median prostate volume 43 cc). Baseline median IPSS was 20. Two-thirds had ≥T3 prostate cancer, and 48% were NCCN very high risk. Median number of implants was 4. Adjunct procedures were required in 19%. All procedures were day case, with median operative time of 14 min. Postoperative catheterisation occurred in 33%, with all patients successfully completing trial without catheter. One Clavien–Dindo grade IIIa complication occurred. At six weeks, PGI-I responses were available for 12 COSTAR participants, of whom 10 (83%) reported feeling ‘much better’ or ‘very much better. All patients completed radiotherapy. Conclusions In this small multicentre pilot study, UroLift prior to prostate radiotherapy was feasible as a day-case procedure, with short operative times, low observed perioperative morbidity and successful catheter removal in all patients requiring temporary postoperative catheterisation. These findings support the procedural feasibility of UroLift as a pre-radiotherapy bladder outlet intervention in appropriately selected men with prostate cancer and provide a basis for further prospective comparative evaluation. Trial registration Clinical Trials.gov ID NCT05840549 2023-01-17.
Authors
- Mieke Van Hemelrijck (ORCID: https://orcid.org/0000-0002-7317-0858)
- Kathie Alexina Wong (ORCID: https://orcid.org/0000-0002-5101-1952)
- David M. Nicol (ORCID: https://orcid.org/0000-0002-3512-6979)
- John Withington (ORCID: https://orcid.org/0000-0002-8250-8013)
- Simone Giona (ORCID: https://orcid.org/0000-0003-2133-5419)
- Charlotte Moss (ORCID: https://orcid.org/0000-0001-6059-0223)
- Netty Kinsella (ORCID: https://orcid.org/0000-0003-3807-9503)
- Vincent S Khoo (ORCID: https://orcid.org/0000-0002-0763-6832)
- Jai H. Seth (ORCID: https://orcid.org/0000-0001-8608-2091)
- Declan J. Cahill (ORCID: https://orcid.org/0000-0001-8618-0724)
- Toby Page (ORCID: https://orcid.org/0000-0002-1961-1405)
- Chris Cottrell
- Holly Townsend-Renn
- Beth Russell
- Ananda Dhansekaran
- Luke Mahoney
- Nicholas James
Publication Details
- Journal
- BMC Urology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1186/s12894-026-02468-9
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00